Compare Amylx Pharmaceuticals Inc (AMLX) vs Sunrun Inc (RUN) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

Sunrun (RUN) trades at $12.47, up 0.08% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong profitability with a net income margin of 17.88% and ROE of 19.06%, while launching a distributed AI data center pilot to leverage its home energy assets. Analyst consensus is bullish with a $17.45 price target, but cash flow from operations remains negative, highlighting financial strain.

The outlook for RUN is mixed: growth potential from virtual power plant initiatives and AI partnerships offers upside, but negative operating cash flow and high debt pose significant risks. Investors should weigh the attractive valuation multiples against operational sustainability and market volatility.